SFOSF OTC
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
1W: +11.4%
1M: +11.4%
3M: +21.3%
YTD: -11.9%
1Y: -30.0%
3Y: +10.9%
5Y: -51.0%
$2.45
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Balance Sheet Trends
Total Assets
$120.1B
+2.2% ▲
5Y CAGR: +7.5%
Total Liabilities
$58.2B
+1.2% ▲
5Y CAGR: +9.1%
Shareholders Equity
$48.7B
+3.1% ▲
5Y CAGR: +5.7%
Cash & Investments
$15.8B
-2.1% ▼
5Y CAGR: +5.7%
Total Debt
$36.7B
+15.7% ▲
5Y CAGR: +8.8%
Net Debt
$23.5B
+29.6% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $10.3B | $16.2B | $13.7B | $13.5B | $13.1B |
| Short-Term Investments | $4.2B | $929M | $1.9B | $2.6B | $2.7B |
| Cash & ST Investments | $14.5B | $17.2B | $15.6B | $16.1B | $15.8B |
| Net Receivables | $6.5B | $8.2B | $9.7B | $9.4B | $9.5B |
| Inventory | $5.5B | $6.9B | $7.5B | $7.3B | $6.3B |
| Other Current Assets | $609M | $4.0B | $67M | $817M | $2.3B |
| Total Current Assets | $30.4B | $35.3B | $33.8B | $34.5B | $33.8B |
| Property, Plant & Equip. | $13.3B | $16.0B | $23.7B | $23.4B | $27.8B |
| Goodwill & Intangibles | $22.8B | $26.3B | $28.9B | $30.2B | $28.7B |
| Long-Term Investments | $19.7B | $24.6B | $25.6B | $23.3B | $27.5B |
| Other Non-Current Assets | $6.8B | $4.5B | $337M | $5.3B | $1.3B |
| Total Non-Current Assets | $62.9B | $71.9B | $79.7B | $83.0B | $86.2B |
| Total Assets | $93.3B | $107.2B | $113.5B | $117.5B | $120.1B |
| — Liabilities — | |||||
| Accounts Payable | $5.1B | $6.3B | $6.2B | $6.0B | $4.9B |
| Short-Term Debt | $14.5B | $11.9B | $14.7B | $18.7B | $21.7B |
| Deferred Revenue | $8.2B | $1.5B | $0 | $0 | $1.3B |
| Other Current Liabilities | $8.6B | $15.3B | $13.3B | $5.9B | $8.3B |
| Total Current Liabilities | $29.3B | $33.3B | $33.8B | $37.5B | $36.4B |
| Long-Term Debt | $9.0B | $12.1B | $13.5B | $10.4B | $11.9B |
| Other Non-Current Liab. | $2.3B | $3.0B | $7.5B | $3.2B | $3.0B |
| Total Non-Current Liabilities | $15.6B | $19.8B | $23.1B | $20.1B | $21.8B |
| Total Liabilities | $44.9B | $53.1B | $56.9B | $57.5B | $58.2B |
| — Equity — | |||||
| Common Stock | $2.6B | $2.7B | $2.7B | $2.7B | $2.7B |
| Retained Earnings | $21.0B | $26.2B | $24.5B | $26.6B | $0 |
| Accumulated OCI | $4.4B | -$1.2B | -$1.3B | $0 | $0 |
| Total Stockholders Equity | $39.2B | $44.6B | $45.7B | $47.3B | $48.7B |
| Total Liabilities & Equity | $93.3B | $107.2B | $113.5B | $117.5B | $120.1B |
| — Key Metrics — | |||||
| Total Debt | $24.2B | $30.2B | $30.3B | $31.7B | $36.7B |
| Net Debt | $13.9B | $14.0B | $16.6B | $18.2B | $23.5B |
| Total Investments | $23.9B | $25.5B | $27.4B | $25.9B | $30.1B |